Thyroid Medication and Antidepressants for Treating Major Depression

Completed · Phase 4 · Has a placebo group

Conditions studied: Major Depression

In brief

This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).

Key facts

Study ID

NCT00208702

Run by

Emory University

People needed

153

Starts

1996-09-01

Expected to finish

2003-07-01

Last updated by the study team

2015-11-17

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female between the ages of 18 and 60. (The upper age is limited to 60 because thyroid changes, including blunting of the TSH response to TRH occurs with age and can potentially confound the relationship between the HPT axis and MDD.)
• Primary diagnosis of unipolar Major Depressive Disorder
• HAM-D (21 item) score >18

You may not qualify if…

• Alcohol abuse or alcohol dependence within the past year.
• Psychoactive substance abuse or dependence within the past year.
• Clinical evidence of severe Personality Disorder that would make study participation and completion unlikely.
• ECT within the past 6 months.
• Grade I hypothyroidism defined as low thyroid hormone levels with an associated elevated TSH; hyperthyroidism defined as elevated thyroid hormone concentrations with a low TSH.
• Serious and unstable medical illnesses.

Where it is running

• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.